Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
TMB or not TMB as a biomarker: That is the question
HTML
Details
Locations
Year:
2021
Type:
review
Source:
Critical Reviews in Oncology/Hematology
DOI:
10.1016/j.critrevonc.2021.103374
Authors:
Alfredo Addeo,
Alex Friedlaender,
Giuseppe L. Banna,
Glen J. Weiss
Institutions:
University Hospital of Geneva,
Générale-Beaulieu Clinic,
Portsmouth Hospitals NHS Trust
Language:
English
Topic:
Cancer Immunotherapy and Biomarkers
Subfield:
Oncology
Field:
Medicine
Domain:
Health Sciences
Keywords:
tumor mutational burden,
immune checkpoint inhibitors,
predictive biomarkers,
pembrolizumab,
pan-cancer biomarker,
PD-L1 expression,
neoantigens,
non-small cell lung cancer,
melanoma,
overall survival,
KEYNOTE-158,
patient selection
show all 12
SDG:
Good health and well-being
Open Access status:
closed
OpenAlex ID:
W3164167181
FWCI:
5.48
Cites:
68
Cited by:
245
Related to:
10